Biogen 10-Q: Q3 Revenue Up 11% to $2.80B, GAAP EPS $(0.14) on $283.8M IPR&D Charges
BIIB sits 83% above its 52-week low of $138.
Summary
Biogen's Q3 10-Q shows revenue up 10.6% to $2.80 billion but a GAAP loss of $20.6 million on $283.8 million of IPR&D charges, with cash down to $1.3 billion after the $5.1 billion Apellis deal and borrowings up to $7.7 billion.
Key Events · Earnings and Guidance · BIIB
-
Q3 Revenue Grows 10.6% to $2.80B
Total revenue of $2,804.1 million rose from $2,534.7 million, with product revenue up 13.1% to $2,088.7 million and new Specialized Immunology products SYFOVRE and EMPAVELI contributing $242.8 million.
-
GAAP Loss on $283.8M IPR&D Charges
Net loss attributable to Biogen was $20.6 million, or $(0.14) diluted, versus $466.5 million of income a year ago, driven by $283.8 million of acquired IPR&D, upfront and milestone expense — primarily the $225.0 million RayThera payment — and $66.5 million of restructuring charges.
-
Cash Falls to $1.3B After Apellis Deal
Cash, cash equivalents and marketable securities totaled $1,303.9 million at September 30, 2026 versus $4,247.6 million at December 31, 2025, after $5,071.1 million paid for Apellis net of cash acquired; total borrowings rose to $7,692.0 million from $6,286.8 million.
-
Nine-Month Operating Cash Flow $1.74B
Net cash from operations was $1,735.2 million for the nine months, roughly flat versus $1,692.7 million a year ago, and management states existing funds plus operating cash flow and financing access are sufficient for the foreseeable future.
Analysis · BIIB · Life Sciences
The 10-Q fills in the numbers behind this morning's 8-K and Reuters beat: revenue of $2,804.1 million rose 10.6% year over year, but GAAP net income swung to a $20.6 million loss because of $283.8 million of acquired IPR&D, upfront and milestone expense — mostly the $225.0 million RayThera payment — plus $66.5 million of restructuring. The balance sheet is the part investors should focus on: cash and marketable securities fell to $1,303.9 million from $4,247.6 million at year-end after the $5.1 billion Apellis deal, while total borrowings rose to $7,692.0 million. That leaves far less cushion, so the $1.7 billion of nine-month operating cash flow and the new product launches (SYFOVRE, EMPAVELI, ZURZUVAE, high-dose SPINRAZA) now carry more of the funding burden. The non-GAAP beat and raised EPS floor stand, but the GAAP loss and thinner liquidity are the details the headline skipped.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIIB was trading at $252.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.3B. The 52-week trading range was $138.00 to $254.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.